Victoria Castel

Integration and Analysis of Clinical and Genomic Data of Neuroblastoma applying Conceptual Modeling

Oscar Pastor, José Fabián Reyes Román, Adela Cañete, 2019, ER Forum/Posters/Demos.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Günter Schreier, Ruth Ladenstein, Henrik Schroeder, 2017, The Lancet. Oncology.

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.

Ruth Ladenstein, Victoria Castel, A. Cañete, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

Ruth Ladenstein, Gudrun Schleiermacher, Gian Paolo Tonini, 2009, The Lancet. Oncology.

Image‐defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy‐induced variation, and impact on surgical outcomes

Giovanni Cecchetto, Giovanni Erminio, Victoria Castel, 2017, Pediatric blood & cancer.

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Barbara Hero, Andreas Faldum, David Machin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.

Ruth Ladenstein, Jérôme Couturier, Victoria Castel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.

Ruth Ladenstein, Adela Cañete, Victoria Castel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study of proliferation and apoptosis in neuroblastoma. Their relation with other prognostic factors.

Samuel Navarro, Victoria Castel, A. Llombart‐Bosch, 2002, Archives of medical research.

Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors

Marta Piqueras, Samuel Navarro, Rosa Noguera, 2009, Pediatric blood & cancer.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ruth Ladenstein, Henrik Schroeder, Ulrike Pötschger, 2018, The Lancet. Oncology.